Showing 11-20 of 27 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Engineering an artificial pancreas in the gut for the treatment of diabetes | Monash University | Rong Xu | Improving Lives | 01-September-2025 to 31-August-2028 | $285,000.00 |
| A synergistic approach to preventing islet allograft rejection in beta cell replacement therapy | St. Vincent's Institute of Medical Research | Seigmund Lai | Cures | 01-March-2025 to 29-February-2028 | $256,285.00 |
| A simple assay to monitor autoimmune T cell responses in T1D | St. Vincent's Institute of Medical Research | Stuart Mannering | Cures | 01-November-2024 to 31-October-2025 | $122,849.00 |
| Monitoring CD4+ T-cell responses in T1D, MS and SLE | St. Vincent's Institute of Medical Research | Stuart Mannering | Cures | 01-September-2025 to 31-August-2026 | $149,998.36 |
| Harnessing T cell exhaustion for type 1 diabetes prevention | St. Vincent's Institute of Medical Research | Thomas Kay | Cures | 01-November-2023 to 31-October-2026 | $2,250,000.00 |
| Experiences of children with early-stage T1D and their families in three Australian monitoring cohorts: what matters most for engagement in a national program? | The University of Adelaide | Jennifer Couper | Cures | 01-February-2025 to 31-January-2027 | $179,817.84 |
| Investigating the utility of urine C-peptide in early-stage T1D | The University of Adelaide | Jennifer Couper | Cures | 01-September-2024 to 31-July-2026 | $93,760.34 |
| Improving Glucose Levels while Preventing Ketoacidosis in People with Type 1 Diabetes Receiving SGLT1/2 inhibitor Therapy Using a Novel Continuous Ketone Sensor (PARTNER) | The University of Melbourne | David O'Neal | Improving Lives | 01-November-2024 to 31-October-2026 | $221,126.00 |
| Understanding RAGE Expression and Function in Human T and Dendritic Cells to Refine the Use of RAGE Targeting Therapeutics for Type 1 Diabetes Prevention. | The University of Queensland | Josephine Forbes | Cures | 01-April-2024 to 31-March-2026 | $200,000.00 |
| FAME-1 Eye Trial Completion | The University of Sydney | Alicia Jenkins | Improving Lives | 01-July-2025 to 30-June-2028 | $545,454.35 |